S0800 Safety and Efficacy of Vedolizumab vs Tumor Necrosis Factor Antagonists in an Elderly IBD Population

Autor:	Sara N. Horst, Dawn B. Beaulieu, Elizabeth A. Scoville, C. Alex Wiles, David A. Schwartz, Baldeep S. Pabla, Chris Slaughter, Robin Dalal
Rok vydání:	2020
Předmět:	Oncology education.field_of_study medicine.medical_specialty Hepatology business.industry Population Gastroenterology Vedolizumab Internal medicine Medicine Tumor necrosis factor alpha education business medicine.drug
Zdroj:	American Journal of Gastroenterology. 115:S410-S410
ISSN:	1572-0241 0002-9270
DOI:	10.14309/01.ajg.0000705248.77205.de
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::ba5e1c1d991847e14e928569654d7d28 https://doi.org/10.14309/01.ajg.0000705248.77205.de Zobrazit plný text záznamu